Podcasts about Heart failure

On this episode of JHLT: The Podcast, the Digital Media Editors invite co-lead author Nir Uriel, MD, Director of Advanced Heart Failure and Cardiac Transplantation at New York Presbyterian Hospital and Professor of Medicine at Columbia University. Dr. Uriel joins to discuss the work of the Cardiogenic Shock Working Group (CSWG) and their recent paper, “Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis.” The discussion explores: Why patients on longer duration of MCS had better survival but maintained similar rates of serious adverse events (SAEs) Why the study might show fewer SAEs than the literature historically shows How temporary MCS devices are selected in clinical settings in patients with cardiogenic shock The ongoing and upcoming activities of CSWG For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Type 2 diabetes directly damages your heart's ability to make energy, leaving you more vulnerable to fatigue, swelling, and heart failure Human heart tissue studies show that mitochondria — the power plants of your cells — lose key components in diabetic hearts, forcing the heart to beat with less fuel Fat and sugar metabolism both become inefficient, and backup fuels fail to provide support, leaving your heart stranded without reliable energy sources Structural changes inside the heart, including scar-like collagen buildup and weaker calcium-handling proteins, make each heartbeat less coordinated and less powerful You can take action by cutting linoleic acid (LA) from your diet, choosing the right carbohydrates, limiting environmental toxins, using sunlight strategically, and tracking your insulin resistance with HOMA-IR to protect your heart's energy systems

On this episode of JHLT: The Podcast, the Digital Media Editors invite author Dr. Ayumi Goda, from the Kyorin University Hospital in Tokyo, Japan, to discuss her team's paper, “Prevalence of occult HFpEF and age-specific efficacy of passive leg raise in pulmonary hypertension.” The discussion explores: How clinical observations led to the idea for a study on whether the passive leg raise could unmask occult HFpEF The potential diagnostic value of the passive leg raise in differing patient populations Age-specific cutoffs that may influence what kind of testing to use in clinical practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

We have a classic episode for you. Preserve your sanity while treating heart failure with preserved ejection fraction.  Dr Michelle Kittleson @MKittlesonMD (Cedars Sinai) illuminates this confounding cardiac condition. Sponsors Sponsor: FIGS Curbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX. Sponsor: Permanente Medical Group Discover more at northerncalifornia.permanente.org. Sponsor: UNCOMMON GOODS To get 15% off your next gift, go to UNCOMMONGOODS.com/curb.

At the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025, hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, discussed the evolving role of oral diuretic intensification as a potential endpoint in heart failure clinical trials. Historically, endpoints progressed from all-cause mortality to cardiovascular mortality, then to composites that included heart failure hospitalization and urgent outpatient visits. Recent trials have gone further, considering changes in oral loop diuretic therapy as signals of worsening disease. The rationale for including oral diuretic intensification is its frequency, prognostic value, and potential to increase event capture in trials. Data from real-world cohorts and secondary analyses demonstrate that escalation of oral diuretics is associated with increased risks of hospitalization and death, suggesting it is not a benign event. Incorporating these events could enhance trial efficiency by substantially increasing the number of captured endpoints, allowing for smaller and shorter studies while maintaining clinical relevance. However, challenges remain. Definitions vary across studies, raising questions about what constitutes a meaningful intensification—dose doubling, drug class switching, or short-term use of additional diuretics. Distinguishing heart failure–related changes from adjustments for comorbid conditions such as kidney disease or obesity further complicates endpoint validity. Concerns also exist that clinician-driven medication changes may introduce variability or bias unless standardized symptom-based criteria are applied. Despite these complexities, retrospective analyses suggest consistent findings across different statistical approaches, reinforcing the prognostic importance of oral diuretic changes. Broader adoption would require consensus definitions, regulatory acceptance, and frameworks to account for overlapping events, such as escalation followed by IV diuretics or hospitalization. The speakers concluded that oral diuretic intensification represents an important step toward more inclusive and globally applicable trial endpoints that better capture the continuum of worsening heart failure. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. References: Greene SJ, Butler J. Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics. Circulation. 2023;148(22):1746-1749. doi:10.1161/CIRCULATIONAHA.123.066915 Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 Chapters 00:00 - Introduction and Evolution of Heart Failure Endpoints  03:02 - The Case for Oral Diuretic Intensification as an Endpoint 07:06 - Challenges in Adoption and Standardization 14:45 - Broader Implications and Summary

Hear from our experts on identifying opportunities for nsMRA use in treating HF and integrating nsMRAs into current HF treatment algorithms. Credit available for this activity expires: 9/3/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002874?ecd=bdc_podcast_libsyn_mscpedu

Show notes at pharmacyjoe.com/episode1063. In this episode, I'll discuss the risk of hypotension when giving IV furosemide for acute decompensated heart failure. The post 1063: Should you worry about hypotension when giving IV furosemide for acute decompsensated heart failure? appeared first on Pharmacy Joe.

More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I PARACHUTE HF First Evidence of Treatment Benefit in Chagas Heart Failure https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q DAPA ACT HF-TIMI 68 https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575 III AMALFI Trial of AF Screening Remote ECG Screening Ups Atrial Fibrillation Detection ‘Modestly' https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482 STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090 Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Updates on GLP-1 drugs in heart failure, β-blockers after myocardial infarction, the shingles vaccine, and more: Felix Mahfoud, MD, chair of the Department of Cardiology at University Hospital Basel, shares clinical research highlights from the recent European Society of Cardiology Congress. Related Content: GLP-1 Drugs in Heart Failure, β-Blockers After MI, the Shingles Vaccine, and More From ESC 2025

Send us a textWelcome back Rounds Table Listeners! We are back today with a special Rapid Fire Podcast. This week, Drs. Mike and John Fralick discuss some of the top papers from the 2025 European Society of Cardiology (ESC) Congress. Hot off the presses, here we go!Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias (0:00 - 5:23)Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (5:24 - 10:23)RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults (10:24 - 16:09)Apixaban for Extended Treatment of Provoked Venous Thromboembolism (16:10 - 20:55)The Good Stuff (20:56 - 22:53):Thrombo Trial Files (https://thrombotrialfiles.substack.com/)John Candy: I Like Me at the Toronto International Film Festival The I'm Pharmacy podcast is now live on www.medicinepods.com Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Last week, John was at the European Society of Cardiology conference in Madrid, and Adam was at the Preventing Overdiagnosis 2025 International Conference in Oxford. A conversation about what we learned.Digitoxin in Patients with Heart Failure and Reduced Ejection FractionBeta-Blockers Post-MI: A Clear Clinical MessageAspirin in Patients with Chronic Coronary Syndrome Receiving Oral AnticoagulationHow does decontextualised risk information affect clinicians' understanding of risk and uncertainty in primary care diagnosis? A qualitative study of clinical vignettesHow do we talk about overdiagnosis of mental health conditions without dismissing people's suffering? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

Interview with Frederick L. Ruberg, MD, and Mathew S. Maurer, MD, authors of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. Hosted by Sadiya Khan, MD. Related Content: Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure

Interview with Frederick L. Ruberg, MD, and Mathew S. Maurer, MD, authors of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. Hosted by Sadiya Khan, MD. Related Content: Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure

In this podcast accompanying the September issue of DTB (https://dtb.bmj.com/content/63/9), David Phizackerley (DTB Editor) is joined by Syba Sunny (DTB Clinical Editor). David and Syba discuss the editorial that highlights changes to antibiotic susceptibility reports, and in particular, the change to the 'I' classification from 'intermediate' to 'susceptible, increased exposure' (https://dtb.bmj.com/content/63/9/130). They talk about a DTB Select article that summarises an evidence review of deprescribing interventions in primary care and the importance of collaborative multidisciplinary teams, education and training, and shared-decision making (https://dtb.bmj.com/content/63/9/131). They finish by discussing the main article that provides an overview of pharmacological management of chronic heart failure with reduced ejection fraction and the four main groups of drugs that form the four pillars of treatment (https://dtb.bmj.com/content/63/9/133).   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this episode, Dr. Harlan Krumholz reviews the September 9, 2025 issue of JACC, covering key studies on artificial intelligence in cardiovascular research, the effects of tirzepatide in heart failure with preserved ejection fraction (HFpEF), and how social, racial, and genetic factors influence heart failure risk. He discusses the growing burden of heart failure in the elderly, the need to disaggregate data in Asian American and Pacific Islander populations, and the role of rare genetic variants in atrial fibrillation outcomes. The episode also features perspectives on clinical trial design, complex case reports, and emphasizes the need for AI submissions to meet high standards of clinical relevance, feasibility, and long-term impact.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Ahmet Bilgili, from the University of Florida's Congenital Heart Center, and senior author Eric I. Jeng, MD, from the University of Florida's MCS program. Bilgili and Dr. Jeng discuss their paper, “Optimal pretransplant duration with HeartMate III left ventricular assist device: A contemporary analysis.” The discussion explores: Prior gaps in the literature regarding contemporary HM3 outcomes in relation to transplantation—and the study's potential influence on policy Which length of HM3 support influenced better post-transplant outcomes—and which ages were most influenced How these findings might change standard practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

KYW Newsradio's Rasa Kaye and Deborah Heart and Lung center Cardiologist Geurys Rojas-Marte, MD continue their conversation on how individuals can prevent or manage risk factors for heart failure. They also talk about the latest advancements in heart failure treatment at any stage.

The dynamics of AFib and Heart Failure often lead to patients navigating both diseases simultaneously. Learn how to apply effective strategies for management, including team-based care, shared decision-making, addressing adherance barriers, and more, in this conversation with Kathy Wood, PhD, RN, FAHA, FAAN, and Eryn Bryant, MSN, APRN-CNP, FPCNA.PCNA Resources:Atrial Fibrillation:https://pcna.net/health-topics/atrial-fibrillation/ Heart Failure: https://pcna.net/health-topics/heart-failure/EAST-AF NET-4 Trial: acc.org/Latest-in-Cardiology/Clinical-Trials/2020/08/28/16/16/EAST-AFNET-4AFFIRM Trial: https://pubmed.ncbi.nlm.nih.gov/12466506/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Please visit answersincme.com/QWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure. Upon completion of this activity, participants should be better able to: Identify the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure; Evaluate clinical implications of the latest data on nonsteroidal MRAs for the treatment of heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF), in the context of current standard-of-care; and Describe strategies to incorporate nonsteroidal MRAs into the treatment plans of patients with HFmrEF or HFpEF.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Estimated Glomerular Filtration Rate Variability and Incident Heart Failure in Adults With Type 2 Diabetes.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Predictors of Length-of-Stay Among Transcatheter Aortic Valve Replacement Patients Using a Supervised Machine Learning Algorithm.

Back in 2013, Michelle Hocking was 41 and “overweight and overwhelmed with depression, anxiety and panic attacks”.Then one Saturday afternoon in July 2013, she struggled to walk 5 metres without being short of breath.Less than 24 hours later, she was diagnosed with viral cardiomyopathy. Her husband was asked if her affairs were in order and a heart transplant was being discussed.Fast forward 5 years and life is very different.Michelle (Chell) is now a trail runner and an ultra-marathon runner, having completed the 2017 UTA 50km and in October this year, 2018, she'll line up at the start of the 74km Taupo Ultra Marathon.In this conversation, she shares her remarkable story and her advice to you.

Varun Sundaram, MD, PhD, discusses how his experiences shaped his groundbreaking work in global heart failure research, from uncovering international differences in patient care to leading studies on GLP-1 therapies and advanced heart failure. Learn more about Varun Sundaram, MD, PhD Learn more about the University Hospitals Research & Education Institute Follow Us on Social:      

Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.

Focus Issue on Heart Failure and Cardiomyopathies

This month KYW Newsradio's Rasa Kaye and Deborah Heart and Lung center Cardiologist Geurys Rojas-Marte, MD discuss how individuals can prevent or manage risk factors for heart failure. They also talk about the latest advancements in heart failure treatment at any stage.

Heart failure remains one of the most urgent challenges in health care, affecting millions of individuals and imposing a significant burden on families and the broader health system. Although guideline-directed medical therapy (GDMT) has been shown to improve clinical outcomes and reduce hospitalizations, adoption of these therapies remains suboptimal nationwide. Addressing this treatment gap is essential not only for enhancing survival and quality of life but also for mitigating the rising economic impact of heart failure as its prevalence continues to increase. Gluckman also led the session “Addressing Underuse of Guideline-Directed Medical Therapy in Heart Failure” at the July 9 Institute for Value-Based Medicine® (IVBM) event in Garden Grove, CA, where he addressed the need for integrated approaches to drive sustainable, system-level change in cardiovascular care. On this episode of Managed Care Cast, Ty Gluckman, MD, MHA, FACC, FAHA, FASPC—a practicing cardiologist at Providence Heart Institute in Portland, Oregon, and medical director of Providence's Center for Cardiovascular Analytics, Research, and Data Science—discusses strategies to improve GDMT implementation. The conversation explores opportunities for payers and providers, the potential of remote patient monitoring and digital health tools, and the role of value-based care models in supporting optimal therapy. Emphasis is placed on the importance of aligning clinical guidelines with managed care policies to drive meaningful improvements in patient outcomes.

Testosterone TEST IS BEST - Bodybuilding Podcast ep. 76#bodybuilding #TRT #Muscle #Contestprep #bodybuildingpodcastMy Book:ULTIMATE GUIDE TO ROIDS #1 BOOK ON TRUTH IN THE HISTORY OF BODYBUILDING Link -⁠ ⁠⁠⁠⁠⁠⁠⁠⁠https://bodybuilderinthailand.com/ultimate-guide-to-roids/⁠⁠⁠⁠⁠⁠⁠⁠⁠Daily Text Msg Training 99/month and 1 Hour Phone Call Consult 59 Email to inquire about personal training to steroidspodcast@gmail.comBodybuilder in Thailand on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/bodybuilderinthailand/⁠⁠⁠⁠⁠My Other Podcast: Grab the Bull Podcast: ⁠⁠⁠⁠⁠https://youtu.be/X6SzfCrN4NY?si=Ho2T9WIVxLjXo_AE⁠⁠Time Stamps:0:00 Ferocious Libido on a steroid cycle of Low Test High Tren - Low Sex Drive on a Cruise4:20 Proviron and Masteron - Libido - Acne - Prostate - Talking about Masteron Enanthate8:12 Getting off Gear Due to Health Problems - Losing alot of Muscle10:52 Alot of Big Guys like the way 1000mg Testosterone Per Week Feels, and don't like to go below that.15:34 DHEA and Pregnenolone20:45 1000mg of Testosterone per week Every Single Big Guy I Know Says it was the Biggest Game Changer24:03 Heart Failure and Wants to Cycle Steroids26:00 Left Ventricular Hypertrophy Steroid Heart Growth is Reversible27:33 Winstrol Optimal Cycle Duration and In Depth Real World Use of this Incredible Hormone for Bodybuilding30:17 Cutting Cycle on High Testosterone33:42 Masteron and Primobolan Shortage - What Other hormones can replace them35:55 Anavar Big Pharma - Viagra Sildenafil - Glp1 Agonists - Ozempic 39:11 How to Tell if you have GYNO Bitch TITS - Ronnie Coleman won the 1998 Mr Olympia with Severe GYNO43:00 What Foods to Eat before training first thing in the morning - PROATS whey protein and oats45:55 Best Exercises For Muscle Mass for Each Bodypart - Barbell Pause Bench Press for Chest48:00 Dumbell Row Explanation for massive gains51:53 Trenbolone Long and Short Esters - PARABOLAN Trenbolone hexahydrobenzylcarbonate GH15 god of hormones56:35 Testosterone and Primobolan Ratio - Sensitive to Estrogen from Testosterone and DbolThis Podcast is for entertainment and conversational purposes only. Serious Injury and Death can occur from utilizing chemical performance enhancement. This author does not support the use of illegal performance enhancing drugs. If any substances mentioned in this video are illegal in your country do not use them. The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice.

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2024:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) (0:00 – 4:09)Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) (4:10 – 9:28)Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) (9:29 – 14:23)Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH) (14:24 – 20:28)Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (BALANCE) (20:29 – 23:59)And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (24:00 - 25:23)Calling keen trainees!Trainees, med students, residents: The Rounds Table and Trial Files (https://trialfiles.substack.com/) are looking for keen individuals to support our efforts.Reach out to fralickmpf@gmail.com if you are interested in getting involved. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

“When a patient comes in for a routine outpatient echo, we’ll be able to help with diagnosis and reduce the misdiagnosis at that point, number one,” Ultromics’ Founder and CEO Ross Upton explains to Bloomberg Intelligence analyst Matt Henriksson about the initial benefits of EchoGo for heart failure and cardiac amyloidosis. In this episode of the Vanguards of Health Care podcast, Upton also delves into the future of diagnosing and treating heart failure with artificial intelligence, saying it can additionally “really accurately phenotype them, and so the clinician would understand after the echo is done what treatments or what next diagnostic tests the patient needs, and they would understand it there and then without having to go through and try and figure out the pieces of the puzzle.” Also tune in to learn how Ultromics plans to use to recently announced Series C financing as it commercializes EchoGo for heart failure and cardiac amyloidosis.See omnystudio.com/listener for privacy information.

In this focus issue on Heart Failure in Practice, JACC Editor-in-Chief Dr. Harlan Krumholz examines how contemporary research continues to refine and at times challenge our understanding of heart failure management. This week's episode features a first-of-its-kind trial on dual therapy with SGLT2 inhibitors and MRAs, new real-world data on heart failure with improved EF, and sobering insights into what happens when foundational therapies are withdrawn. Also explored: sex-specific risks in genetic cardiomyopathies, the limitations of standard stroke prediction tools, and the case for modernizing ICD eligibility criteria. As always, the episode concludes with a synthesized summary of key takeaways for clinicians.

**NEW PODCAST WITH NEW CONTENT** Zak's new show, the RD Exam Ready Podcast will be featuring NEW EPISODES of study material! Listen in for a featured episode about the pathology and MNT for Heart Failure! Subscribe to the RD Exam Ready Podcast.Watch on Youtube IG: @RDexamready

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long, MD (@long_brit), we cover sympathetic crashing acute pulmonary edema (SCAPE). To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play 

In this episode of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz introduces the journal's new design and highlights key studies from the July 29, 2025 issue. Topics include the under-expansion analysis of the ACURATE NEO2 valve, the impact of tirzepatide in obesity-related HFpEF, the effects of private equity ownership on heart failure care, and evolving strategies for managing multivalve disease.

Send us a textIn this episode, CMMI Director Abe Sutton shares his unique journey from the private sector back to government service and reveals how he's rapidly transforming Medicare through innovative payment models. Sutton discusses the newly launched WISER (Wasteful and Inappropriate Service Reduction) model, which leverages AI technology to reduce fraud and waste in Medicare, and the upcoming ASM (Ambulatory Specialty Model) targeting heart failure and lower back pain. The conversation explores CMMI's 2025 strategy focused on evidence-based prevention, patient empowerment, and choice and competition, while addressing how emerging technologies like generative AI are creating unprecedented opportunities to streamline healthcare administration and improve patient outcomes. Sutton also reveals how he spent four years during his "off season" developing a comprehensive roadmap for healthcare innovation that he's now implementing at warp speed.Links:WISeR (Wasteful and Inappropriate Service Reduction) model: https://www.cms.gov/priorities/innova...ASM (Ambulatory Specialty Model): https://www.cms.gov/priorities/innova...CMMI's 2025 Strategy Focus: https://www.cms.gov/priorities/innova...Learn how AI can amplify your care coordination team by visiting https://link.careco.ai/HTRKQsTimestamps:00:00:00 - Introduction and Welcome00:00:37 - Why Leave Private Sector for Government Service00:09:16 - AI and Technology's Impact on Healthcare Innovation00:17:49 - WISER Model Introduction and Goals00:30:45 - Food Policy and Making America Healthy Again00:34:08 - ASM Model for Heart Failure and Lower Back Pain00:38:31 - Four Years of Preparation During "Off Season"

Heart failure is one of the most complex and high-risk conditions med-surg nurses manage. In this episode, the co-hosts offer their personal nursing tips to help you monitor, educate, and care for patients with heart failure. Also, find out how Marcela's first neighborhood yard sale went and hear the latest update on Sydney's wedding planning.  MEET OUR CO-HOSTS Samantha Bayne, MSN, RN, CMSRN, NPD-BC is a nursing professional development practitioner in the inland northwest specializing in medical-surgical nursing. The first four years of her practice were spent bedside on a busy ortho/neuro unit where she found her passion for newly graduated RNs, interdisciplinary collaboration, and professional governance. Sam is an unwavering advocate for medical-surgical nursing as a specialty and enjoys helping nurses prepare for specialty certification.    Kellye' McRae, MSN-Ed, RN is a dedicated Med-Surg Staff Nurse and Unit Based Educator based in South Georgia, with 12 years of invaluable nursing experience. She is passionate about mentoring new nurses, sharing her clinical wisdom to empower the next generation of nurses. Kellye' excels in bedside teaching, blending hands-on training with compassionate patient care to ensure both nurses and patients thrive. Her commitment to education and excellence makes her a cornerstone of her healthcare team.   Marcela Salcedo, RN, BSN is a Floatpool nightshift nurse in the Chicagoland area, specializing in step-down and medical-surgical care. A member of AMSN and the Hektoen Nurses, she combines her passion for nursing with the healing power of the arts and humanities. As a mother of four, Marcela is reigniting her passion for nursing by embracing the chaos of caregiving, fostering personal growth, and building meaningful connections that inspire her work.   Eric Torres, ADN, RN, CMSRN is a California native that has always dreamed of seeing the World, and when that didn't work out, he set his sights on nursing.  Eric is beyond excited to be joining the AMSN podcast and having a chance to share his stories and experiences of being a bedside medical-surgical nurse.   Maritess M. Quinto, DNP, RN, NPD-BC, CMSRN is a clinical educator currently leading a team of educators who is passionately helping healthcare colleagues, especially newly graduate nurses. She was born and raised in the Philippines and immigrated to the United States with her family in Florida. Her family of seven (three girls and two boys with her husband who is also a Registered Nurse) loves to travel, especially to Disney World. She loves to share her experiences about parenting, travelling, and, of course, nursing!   Sydney Wall, RN, BSN, CMSRN has been a med surg nurse for 5 years. After graduating from the University of Rhode Island in 2019, Sydney commissioned into the Navy and began her nursing career working on a cardiac/telemetry unit in Bethesda, Maryland.  Currently she is stationed overseas, providing care for service members and their families.  During her free time, she enjoys martial arts and traveling.   

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I'm a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. In this episode, Dr. Warrick Bishop, a cardiologist and CEO of the Healthy Heart Network, discusses various health topics aimed at improving heart health and overall well-being. He emphasizes the importance of salt reduction, highlighting that the World Health Organization recommends consuming less than one teaspoon of salt daily. Research indicates that potassium-based salt substitutes can significantly reduce stroke and death risks. The podcast also covers bone health, clarifying that vitamin E may not be beneficial for bone density, while vitamins D and K2 are suggested for better bone and vascular health.

Welcome back to this week's Friday Review where I can't wait to share with you the best of the week!     I'm looking forward to reviewing:     Magic Molecule (product review) Four Thousand Weeks (book review) Autoimmune Disease & Heart Failure (research) Collagen & Joint Support (research)     For all the details tune into this week's Cabral Concept 3416 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3416 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!